Evaluation and Degradation Chemistry of Orbifloxacin using LC-MS

Author(s): Edith Cristina Laignier Cazedey, Sanjay Garg, Herida Regina Nunes Salgado

Orbifloxacin (ORBI) was subjected to different ICH (Q1A(R2)) prescribed stress conditions of thermal stress, hydrolysis, oxidation and photolysis. It was stable to dry heat (60 ºC) and photolysis (UV-VIS) in solid form. It showed extensive decomposition under hydrolytic and photolytic conditions in acid, base and neutral solutions. Degradation was also observed in oxidative condition. Degradation products of ORBI formed under different forced conditions were characterized through LC–MS studies. In total, eleven major degradation products (DP1-DP11) were detected. Successful separation of drug and degradation products formed under various stress conditions was achieved on a analytical column SymmetryShield Waters RP18, 5 µm, 250 x 4.6 mm using 5% acetic acid and methanol as mobile phase in a gradient mode at flow rate of 0.5 ml/min. The peaks were detected using a PDA detector set at 290 nm. The method was extended to LC–APCI-MS for characterization of the degradation products and the pathways of decomposition were proposed.

Orbifloxacin, Chemistry degradation, SIAM, LC-APCI-MS, Stability

1. Bonfilio, R, Cazedey, E.C.L., Araújo, M.B., Salgado, H.R.N., 2012. Analytical validation of quantitative high-performance liquid chromatographic methods in pharmaceutical analysis: a practical approach. Crit. Rev. Anal. Chem. 42, 87–100.
2. British Pharmacopoeia, 2011. Her Majesty’s Stationery Office, London. v.1, pp.88−90.
3. Cazedey, E.C.L., Othman, A., Garg, S., Salgado, H.R.N., 2011. A validated stability−indicating LC method for orbifloxacin in the presence of degradation products. Curr. Pharmaceut. Anal. 7, 176−181.
4. Davis, J.L., Papich, M.G., Weingarten, A., 2006. The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. J. Vet. Pharmacol. Ther. 29, 191–197.
5. Ganière, J.P., Médaille, C., Etoré, F., 2004. In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. Res. Vet. Sci. 77, 67-71.
6. Goudah, A., Abo−El−Sooud, K., 2008. Pharmacokinetics and milk penetration of orbifloxacin after intravenous and intramuscular injections to dromedary lactating camels (Camelus dromedaries). J. Vet. Pharmacol. Ther. 31, 276−280.
7. Haines, G.R., Brown, M.P., Gronwall, R.R., Merritt, K.A., Baltzley, L.K., 2001. Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. Can. J. Vet. Res. 65, 181–187.
8. ICH, Guidelines on impurities in new drug products, in: Proceeding of International Conference on Harmonization, IFPMA, Geneva, 2006b.
9. ICH, Guidelines on impurities in new drug substances, in: Proceeding of International Conference on Harmonization, IFPMA, Geneva, 2006a.
10. ICH, Validation of Analytical Procedures: Text and Methodology, International Conference on Harmonization, IFPMA, Geneva, 2005.
11. Ihrke, P.J., Papich, M.G., Demanuelle, T.C., 1999. The use of fluoroquinolones in veterinary dermatology. Vet. Dermatol. 10, 193-204.
12. Marín, P., Escudero, E., Fernández-Varón, E., Cárceles, C.M., 2007. Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. J. Dairy Sci. 90, 4219–4225.
13. Marín, P., Fernández-Varón, E., Escudero, E., Vancraeynest, D., Cárceles, C.M., 2008. Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous, and intramuscular administration. J. Vet. Pharmacol. Ther. 31, 77–82.
14. Martinez, M., Mcdermott, P., Walker, R., 2006. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. Vet. J. 172, 10–28.
15. Matsumoto, S., Nakai, M., Yoshida, M., Katae, H., 1999. A study of metabolites isolated from urine samples of pigs and calves administered orbifloxacin. J. Vet. Pharmacol. Ther. 22, 286-289.
16. Matsumoto, S., Takahashi, M., Kitadai, N., Katae, H., 1998. A study of metabolites isolated from the urine samples of cats and dogs administered orbifloxacin. J. Vet. Med. Sci. 60, 1259-1261.
17. Mckay, L., Rose Crystal, D.S., Matousek, J.L., Schmetizel, L.S., Gibson, N.M., Gaskin, J.M., 2007. Antimicrobial testing of selected fluoroquinolones against Pseudomonas aeruginosa isolated from canine otitis. J. Am. Anim. Hosp. Assoc. 43, 307–312
18. Morimura, T., Kohno, K., Nobuhara, Y., Matsukura, H., 1997b. Photoreaction and active oxygen generation by photosensitization of a new antibacterial fluoroquinolone derivative, orbifloxacin, in the presence of chloride ion. Chem. Pharm. Bull. 45, 1828−1832
19. Morimura, T., Nobuhara, Y., Matsukura, H., 1997a. Photodegradation products of a new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution. Chem. Pharm. Bull. 45, 373-377
20. Morimura, T., Ohno, T., Matsukura, H., Nobuhara, Y., 1995a. Degradation kinetics of the new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution. Chem. Pharm. Bull. 43, 1052-1054
21. Morimura, T., Ohno, T., Matsukura, H., Nobuhara, Y., 1995b. Photodegradation kinetics of the new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution. Chem. Pharm. Bull. 43, 1000-1004
22. Nakamura, S., 1995. Veterinary use of the new quinolones in Japan. Drugs 49, 152–158
23. O’neil, M.J. (Ed.), 2006. The Merck index: an encyclopedia of chemicals, drugs and biologicals, 14th. ed. Merck & Co., Whitehouse Station (NJ). pp. 1182
24. Rang, H.P., Dale, M.M., Ritter, J.M., Moore, P.K., 2003. Pharmacology, 5th ed. Churchill Livingstone, London
25. Reynolds, J.E.F. (Ed), 2007. Martindale the extra pharmacopoeia, 35th.ed. Pharmaceutical Press, London. pp. 278
26. Scott, D.W., Peters, J., Miller Jr, W.H., 2006. Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs. Can. Vet. J. 47, 999–1002
27. Stability testing of new drug substances and products, QIA (R2), in: Proceeding of International Conference on Harmonization (ICH), IFPMA, Geneva, 2003
28. United States Pharmacopeia, 2011. The United States Pharmacopeial Convention, 34th ed. Rockville, MD. pp. 3732−3734
29. Zivanovic, Lj., Zigic, G., Zecevic, M., 2006. Investigation of chromatographic conditions for the separation of ofloxacin and its degradation products. J. Chrom. A 1119, 224–230